References
- Siegel R L, Miller K D. and Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 2016; 66: 7–30. doi:10.3322/caac.21332.
- Morigi C. Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. ecancermedicalscience.2017;11:732. doi:10.3332/ecancer.2017.732.
- Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer 2016; 7(15):2346–2359.
- Ravishankaran, P., & Karunanithi, R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World Journal of Surgical Oncology, 2011; 9, 18.
http://doi.org/10.1186/1477-7819-9-18 . - Wang, H., & Yang, X. Association between serum cytokines and progression of breast cancer in Chinese population. Medicine, 2017;96(49), e8840.
http://doi.org/10.1097/MD.0000000000008840 - Ibrahim S, El-Ghonaimy E, Hassan H, Mahana N, Mahmoud M, TahaniEl-Mamlouk T, El-Shinawi M., Mohamed M. Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression. Journal of Advanced Research, 2016; Volume 7, Issue 5, September, Pages 661–670.
- Abana CO, Bingham BS, Cho JH, et al. IL-6 variant is associated with metastasis in breast cancer patients. Coleman WB, ed. PLoS ONE. 2017;12(7):e0181725. doi:10.1371/journal.pone.0181725.
- Hartman ZC1, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013; Jun 1;73(11):3470–80. doi: 10.1158/0008-5472.CAN-12-4524-T. Epub 2013 Apr 30.
- Xin Zhu, Lingbin Du, Jianguo Feng, et al. Clinicopathological and Prognostic Significance of Serum Cytokine Levels in Breast Cancer. Clinical laboratory, 2013; 60(7):1145–51.
- Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin Cancer Res, 2016; 22(10); 2329–34.
- Mostafa AA, Codner D, Hirasawa K, et al. Activation of ERα Signaling Differentially Modulates IFN-γ Induced HLA-Class II Expression in Breast Cancer Cells. Kovats S, ed. PLoS ONE. 2014;9(1):e87377. doi:10.1371/journal.pone.0087377.
- Marie-Emmanuelle Legrier, et al 2016. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. British Journal of cancer Cancer volume114, pages 177–187.
- NCD Risk Factor Collaboration (NCD-RisC), Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019 May;569(7755):260–264. doi: 10.1038/s41586-019-1171-x. Epub 2019 May 8.
- Gyamfi J, Eom M, Koo JS, Choi J. Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction. Transl Oncol.; 11(2):275–285. doi:10.1016/j.tranon.2017.12.009
- Bowers LW, Brenner AJ, Hursting SD, Tekmal RR, deGraffenried LA. Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production. Breast Cancer Res Treat. 2015;149(1):49–57. doi:10.1007/s10549-014-3223-0
- Bougaret L, Delort L, Billard H, et al. Adipocyte/breast cancer cell crosstalk in obesity interferes with the anti-proliferative efficacy of tamoxifen. PLoS One;2018; 13 (2): e0191571. doi:10.1371/journal.pone.0191571.
- Modified from Schnitt SJ. Will molecular classification replace traditional breast pathology? Int J Surg Pathol. 2010;18:162S–166S.
http://dx.doi.org/10.1177/1066896910370771 . - Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol. 2009;17:285–302.
http://dx.doi.org/10.1177/1066896908328577 . - El Saeed GK, Hosny Abou-elela DM, Ahmed El-Gendy MT. Evaluation of interleukin-6 and C-reactive protein in patients with breast cancer at Menoufia University Hospitals. Menoufia Med J 2016;29:337–40
- Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z et al., Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Sci Rep. 2017 May 11;7(1):1796. doi: 10.1038/s41598-017-01268-4.
- Huang WC, Hung CM, Wei CT, et al. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. Oncotarget, 2016; 7 (38): 62352–62363. doi: 10.18632/oncotarget 11471.
- Vaysse C, Lømo J, Garred O, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, et al. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. npj Breast Cancer, 2017; 3, Article number: 19 (2017).
- Faria SS, Corrêa LH, Heyn GS, de Sant’Ana LP, Almeida RDN, Magalhães KG. Obesity and Breast Cancer: The Role of Crown-Like Structures in Breast Adipose Tissue in Tumor Progression, Prognosis, and Therapy. J Breast Cancer, 2020; May; 23(3):233–245. doi: 10.4048/jbc.2020.23.e35. PMID: 32595986; PMCID: PMC7311368.
- Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med.2018; 7(9):4509–4516. doi: 10.1002/cam4.1700. Epub 2018 Jul 23. PubMed PMID: 30039553; PubMed Central PMCID: PMC6143921.
- Mojic M, Takeda K, Hayakawa Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. Int J Mol Sci. 2017;19(1):89. Published 2017 Dec 28. doi:10.3390/ijms19010089.
- Nagai Y, Tsuchiya H, Ji MQ, Zhang H, Greene MI. Synergistic effect of IFN-γ on breast cancer targeted therapy. The Journal of Immunology, 2017; May, 198 (1 Supplement) 141.14
- Schmidt FM, Weschenfelder J, Sander C, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015; 10(3):e0121971. Published 2015 Mar 17. doi:10.1371/journal.pone.0121971
- Mehta SY, Morten BC, Antony J, et al. Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes. Oncotarget. 2018; 9(49):29146–29161. doi:10.18632/oncotarget.25635